ClinicalTrials.gg
CompletedNCT03779620Updated Oct 15, 2024

Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis

An interventional study of Ultrasound treatment of Calcified aortic valve in Aortic Valve Stenosis, sponsored by Cardiawave SA. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Cardiawave SA · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.

Enrollment
62nd of 69
30 · median 186
Started
2019
with 12 others
No phase
58 of 131
8 open now
Registered
82nd of 131
by date

Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 62nd largest by enrollment of the 69 interventional ones that give a count, is one of 13 that started in 2019, is one of 58 with no phase, and was the 82nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Aortic Valve Stenosis with a site in France, or all of them as a file.
02

Study summary

This is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-man

Read the detailed description

CARDIAWAVE has developed a new non-invasive, real-time image-guided, therapeutic approach to treat patients suffering from Calcified Aortic Stenosis. CARDIAWAVE's Valvosoft device is a new ultrasound therapy based on a disruptive technology involving delivering an extremely precise and focused ultrasound beam to perform a reparative effect on the aortic valve leaflets, softening the valve's tissues, restoring leaflet mobility, and therefore improving the overall clinical status related to the aortic valve stenosis. This is a FIM study

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • symptomatic
  • aortic valve
  • stenosis
  • ultrasound
  • non-invasive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects suffering from severe symptomatic aortic valve stenosis (including subjects with a bicuspid valve).
  2. Patient is not eligible for TAVR/SAVR .
  3. Age ≥18 years.
  4. Subjects who are willing to provide a written prior to participating in the study.
  5. Subjects who can comply with the study follow up or other study requirements.
  6. Subject eligible according to Clinical Review Committee

Exclusion criteria

-

Exclusion Criteria:

  1. Subjects with any electrical device implanted.
  2. Subjects with unstable arrhythmia not controlled by medical treatment.
  3. Subjects with implanted mechanical valve in any position or bio prosthetic valve in aortic position.
  4. Subjects with complex congenital heart disease.
  5. Chest deformity.
  6. Cardiogenic shock.
  7. History of heart transplant.
  8. Subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after treatment.
  9. Thrombus in heart.
  10. Acute myocardial infarction (MI), stroke or (TIA) within one month prior to enrolment*.
  11. Subjects who are pregnant or nursing.
  12. Subjects who are participating in another research study for which the primary endpoint has not been reached.

    -

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Ultrasound treatment

    Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement

    Device: Ultrasound treatment of Calcified aortic valve

Interventions

  • DeviceUltrasound treatment of Calcified aortic valve

    Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement

06

What researchers measure

Primary outcomes

  1. Safety: Rate of procedure related mortality at 30 days

    Rate of procedure related mortality at 30 days

    Time frame: 30 days post-procedure

  2. Device performance to modify valve structure as measured by echocardiography

    Ability to modify the Aortic Valve Area (mm2)

    Time frame: Immediately post-procedure

  3. Device performance to modify valve structure as measured by echocardiography

    Ability to modify the Pressure Gradient (mmHg)

    Time frame: Immediately post-procedure

Secondary outcomes

  1. All-cause mortality and major adverse events (MAE's)

    Rate of all-cause mortality and MAE's peri and postprocedure and at 1, 3, 6, 12 and 24 months post operatively.

    Time frame: Up to 24 months

  2. Non-disabling stroke

    Rate of stroke at 1,3,6, 12 and 24 months

    Time frame: Up to 24 months

  3. Improvement of clinical status

    Improvement of New York Heart Association class (I-IV - stage of severity of heart failure - I=no symptoms, IV= symptoms at rest) at 1,3,6,12, and 24 months.

    Time frame: Up to 24 months

  4. Number of all Adverse Events (AEs)

    Rate of AE's reported at at 1, 3, 6, 12 and 24 months

    Time frame: Up to 24 months

  5. User handeling of Valvosoft

    User handling (questionnaire for operator + procedure duration) immediately post-procedure

    Time frame: Immediately post-procedure

  6. Improvement of quality of life

    Improvement of quality of life by means of Kansas City Cardiomyopathy Questionnaire at 1, 3, 6, 12 and 24 months

    Time frame: upto 24 months

  7. Long term maintenance of improvement of AVA and PG

    Long term maintenance of improvement of AVA and PG at 3, 6, 12 and 24 months

    Time frame: upto 24 months

07

Study locations

2 sites
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Amphia Hospital
    Breda, 4818CK, Netherlands
08

References and documents

Publications

  • Messas E, Ijsselmuiden A, Trifunovic-Zamaklar D, Cholley B, Puymirat E, Halim J, Karan R, van Gameren M, Terzic D, Milicevic V, Tanter M, Pernot M, Goudot G. Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: a cohort study. Lancet. 2023 Dec 16;402(10419):2317-2325. doi: 10.1016/S0140-6736(23)01518-0. Epub 2023 Nov 14. PubMed 37972628 ↗
  • Messas E, IJsselmuiden A, Goudot G, Vlieger S, Zarka S, Puymirat E, Cholley B, Spaulding C, Hagege AA, Marijon E, Tanter M, Bertrand B, Remond MC, Penot R, Ren B, den Heijer P, Pernot M, Spaargaren R. Feasibility and Performance of Noninvasive Ultrasound Therapy in Patients With Severe Symptomatic Aortic Valve Stenosis: A First-in-Human Study. Circulation. 2021 Mar 2;143(9):968-970. doi: 10.1161/CIRCULATIONAHA.120.050672. Epub 2021 Jan 25. No abstract available. PubMed 33486971 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2022, 34 months.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 34 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2018
First posted
Dec 19, 2018
StartActual
Mar 13, 2019
Primary completionActual
Jan 15, 2022
CompletionActual
Sep 27, 2023
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03779620
Lead sponsor
Cardiawave SA
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Mar 13, 2019
Primary completion
Jan 15, 2022
Completion
Sep 27, 2023
Last update
Oct 15, 2024

Study contacts

Emmanuel Messas, MD
principal investigator · HGEP Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion